department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Oric Pharmaceuticals, Inc. ($ORIC) · pharmadog

PUBLIC COMPANY

$ORICOric Pharmaceuticals, Inc.

South San Francisco, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Phase 11Phase 2

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Oric Pharmaceuticals, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$ORIC

SEC CIK

0001796280

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

$ORIC

Data sources

SEC EDGAR · openFDA

last refreshed 59m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase1ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCrecruitingn=76
phase1Study of ORIC-944 in Patients With Metastatic Prostate Cancerrecruitingn=250
phase2Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alterationrecruitingn=350
phase1Study of ORIC-533 in Relapsed or Refractory Multiple Myelomacompletedn=31
phase1Effect of Food on the Pharmacokinetics of ORIC-114completedn=32
phase1Study of ORIC-101 in Combination With Enzalutamideterminatedn=41
phase1Study of ORIC-101 in Combination With Anticancer Therapyterminatedn=83

Insider activity

source: SEC Form 4

open-market buys + sells

Feb 24, 26SELLPiscitelli Dominic· Chief Financial Officer52,000 sh @ $13.51−$703K↗

routine RSU / option mechanics (2)

Feb 24, 26option exercisePiscitelli Dominic · Chief Financial Officer52,000 sh
Feb 24, 26option exercisePiscitelli Dominic · Chief Financial Officer52,000 sh

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?